Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients.

Tharakan S, Zimmerman B, Ru M, Blanter J, Cascetta K, Tiersten A.

Oncology. 2020 Mar 17:1-4. doi: 10.1159/000506076. [Epub ahead of print]

PMID:
32182614
2.

Novel breast cancer treatment leads to hyperglycaemia.

Bass IR, Tiersten A, Trlica K, Ryncarz A, Adler B, Gallagher EJ.

Diabet Med. 2020 Feb 24. doi: 10.1111/dme.14281. [Epub ahead of print] No abstract available.

PMID:
32096251
3.

Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.

Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.

Cancer Chemother Pharmacol. 2020 Feb 13. doi: 10.1007/s00280-020-04030-2. [Epub ahead of print]

PMID:
32055930
4.

BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.

Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A.

Oncology. 2020;98(4):248-251. doi: 10.1159/000504965. Epub 2020 Jan 21.

PMID:
31962330
5.

Physical Symptom Burden and Its Association With Distress, Anxiety, and Depression in Breast Cancer.

McFarland DC, Shaffer KM, Tiersten A, Holland J.

Psychosomatics. 2018 Sep - Oct;59(5):464-471. doi: 10.1016/j.psym.2018.01.005. Epub 2018 Jan 31.

6.

Molecular Imaging of Apoptosis in Cancer Therapy-Related Cardiac Dysfunction Before LVEF Reduction.

Nakahara T, Petrov A, Tanimoto T, Chaudhry F, Narula N, Seshan SV, Mattis JA, Pak KY, Sahni G, Bhardwaj A, Sengupta PP, Tiersten A, Strauss HW, Narula J.

JACC Cardiovasc Imaging. 2018 Aug;11(8):1203-1205. doi: 10.1016/j.jcmg.2017.12.012. Epub 2018 Feb 14. No abstract available.

7.

Prevalence of physical problems detected by the distress thermometer and problem list in patients with breast cancer.

McFarland DC, Shaffer KM, Tiersten A, Holland J.

Psychooncology. 2018 May;27(5):1394-1403. doi: 10.1002/pon.4631. Epub 2018 Feb 1.

8.

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A.

Gynecol Oncol. 2017 Feb;144(2):279-284. doi: 10.1016/j.ygyno.2016.11.043. Epub 2016 Dec 5.

PMID:
27931751
9.

Palliation of Ulcerative Breast Lesions with Radiation.

Vempati P, Knoll MA, Dharmarajan K, Green S, Tiersten A, Bakst RL.

Anticancer Res. 2016 Sep;36(9):4701-5.

PMID:
27630316
10.

Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years.

McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A.

J Oncol. 2016;2016:4324863. doi: 10.1155/2016/4324863. Epub 2016 Jun 13.

11.

Early Childhood Adversity and its Associations With Anxiety, Depression, and Distress in Women With Breast Cancer.

McFarland DC, Andreotti C, Harris K, Mandeli J, Tiersten A, Holland J.

Psychosomatics. 2016 Mar-Apr;57(2):174-84. doi: 10.1016/j.psym.2015.11.008. Epub 2015 Nov 30.

12.

ReCAP: Would Women With Breast Cancer Prefer to Receive an Antidepressant for Anxiety or Depression From Their Oncologist?

McFarland DC, Johnson Shen M, Harris K, Mandeli J, Tiersten A, Holland J, McFarland DC, Johnson Shen M, Harris K, Mandeli J, Tiersten A, Holland J.

J Oncol Pract. 2016 Feb;12(2):172-4; e197-206. doi: 10.1200/JOP.2015.006833. Epub 2016 Jan 19.

13.

A unique presentation of occult primary breast cancer with a review of the literature.

Ahmed I, Dharmarajan K, Tiersten A, Bleiweiss I, Schmidt H, Green S, Bakst RL.

Case Rep Oncol Med. 2015;2015:102963. doi: 10.1155/2015/102963. Epub 2015 Mar 18.

14.

A case of vasculitis in a breast cancer patient treated with T-DM1.

Bhardwaj AS, McLellan B, Robinson MR, Ghaw O, Lipsey LR, Tiersten AD, Morris GJ.

Semin Oncol. 2014 Oct;41(5):e39-45. doi: 10.1053/j.seminoncol.2014.08.010. Epub 2014 Aug 29. No abstract available.

PMID:
25440614
15.

Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases.

Adams S, Novik Y, Oratz R, Axelrod D, Speyer J, Tiersten A, Goldberg JD, Bhardwaj N, Unutmaz D, Demaria S, Formenti S.

J Clin Oncol. 2014 Oct 1;32(28):3204-5. doi: 10.1200/JCO.2014.56.1282. Epub 2014 Aug 4. No abstract available.

PMID:
25092780
16.

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.

Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, Formenti S, Kyriakou V, Joseph B, Goldberg JD, Li X, Adams S, Tiersten A.

Breast Cancer Res. 2014 Mar 31;16(2):R32. doi: 10.1186/bcr3634.

17.

Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.

Warner E, Liebes L, Levinson B, Downey A, Tiersten A, Muggia F.

Oncologist. 2014 Mar;19(3):250. doi: 10.1634/theoncologist.2013-0398. Epub 2014 Feb 21.

18.

A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.

Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F.

Int J Gynecol Cancer. 2013 Nov;23(9):1577-82. doi: 10.1097/IGC.0b013e3182a809e0.

19.

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S.

Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5.

20.

Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.

Safra T, Andreopoulou E, Levinson B, Borgato L, Pothuri B, Blank S, Tiersten A, Boyd L, Curtin J, Muggia F.

Anticancer Res. 2010 Sep;30(9):3243-7.

PMID:
20944093
21.

A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.

Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM.

Gynecol Oncol. 2010 Sep;118(3):303-7. doi: 10.1016/j.ygyno.2010.05.020. Epub 2010 Jun 14.

22.

Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer.

Fasano J, Hershman D, Novik Y, Levinson B, Blozie K, Tiersten AD.

Breast Care (Basel). 2010 Mar;5(1):17-21. Epub 2010 Feb 2.

23.
24.

Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, Markman M.

Gynecol Oncol. 2009 Aug;114(2):206-9. doi: 10.1016/j.ygyno.2009.04.023. Epub 2009 May 23.

25.

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.

Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS.

Gynecol Oncol. 2009 Mar;112(3):444-9. doi: 10.1016/j.ygyno.2008.10.028. Epub 2009 Jan 12.

26.

Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer.

Vahdat LT, Cohen DJ, Zipin D, Lo KS, Donovan D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS.

Bone Marrow Transplant. 2007 Aug;40(3):267-72. Epub 2007 Jun 11.

PMID:
17563739
27.

Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer.

Tiersten A, Selleck M, Smith DH, Wertheim I, Kaufman E, Hershman D, Vahdat LT, Savage DG, MacArthur RB, Hesdorffer C.

Int J Gynecol Cancer. 2006 Jan-Feb;16(1):57-64.

PMID:
16445611
28.

Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature.

Crew KD, Cohen MH, Smith DH, Tiersten AD, Feirt NM, Hershman DL.

Gynecol Oncol. 2005 Jan;96(1):235-40. Review.

PMID:
15589608
29.

Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.

Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, Savage D, Troxel A.

Breast. 2004 Aug;13(4):341-6.

PMID:
15325671
30.

Relationship between mammographic breast density and tamoxifen in women with breast cancer.

Tiersten A, Ng YY, Pile-Spellman E, Nelsen C, Noguera-Irizarry W, Brafman R, Russo D, Troxel A, Johnson A.

Breast J. 2004 Jul-Aug;10(4):313-7.

PMID:
15239789
31.

Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.

Tiersten AD, Selleck MJ, Hershman DL, Smith D, Resnik EE, Troxel AB, Brafman LB, Shriberg L.

Gynecol Oncol. 2004 Feb;92(2):635-8.

PMID:
14766258
32.

Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer.

Hershman D, Weinberg M, Rosner Z, Alexis K, Tiersten A, Grann VR, Troxel A, Neugut AI.

J Natl Cancer Inst. 2003 Oct 15;95(20):1545-8.

PMID:
14559877
33.

A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma.

Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP.

Cancer. 2003 Feb 1;97(3):537-44.

34.

Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.

Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS.

Bone Marrow Transplant. 2002 Aug;30(3):149-55.

35.

Complementary and alternative medicine: the role of the cancer center.

Antman K, Benson MC, Chabot J, Cobrinik D, Grann VR, Jacobson JS, Joe AK, Katz AE, Kelly K, Neugut AI, Russo D, Tiersten A, Weinstein IB.

J Clin Oncol. 2001 Sep 15;19(18 Suppl):55S-60S. No abstract available.

PMID:
11560974
36.

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).

Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS.

Gynecol Oncol. 2001 Aug;82(2):317-22.

PMID:
11531286
37.

Reduction of paclitaxel-induced peripheral neuropathy with glutamine.

Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C.

Clin Cancer Res. 2001 May;7(5):1192-7.

38.

High-dose chemotherapy for breast cancer: evolving data.

Antman K, Tiersten A.

Oncology (Williston Park). 1999 Sep;13(9):1215-9. Review. No abstract available.

39.

Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.

Vahdat LT, Papadopoulos K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E, Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, Heitjan D, Antman K, Hesdorffer C.

Clin Cancer Res. 1998 Jul;4(7):1689-95.

40.
41.

Acute hypertensive crisis following octreotide administration in a patient with malignant pheochromocytoma.

Saltz L, Tiersten A, Hassan B, Groeger J.

Oncol Rep. 1995 Nov;2(6):1129-30.

PMID:
21597869
42.

Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.

Vahdat L, Raptis G, Fennelly D, Hamilton N, Reich L, Tiersten A, Harrison M, Hudis C, Moore M, Yao TJ, et al.

Clin Cancer Res. 1995 Nov;1(11):1267-73.

43.

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, et al.

J Clin Oncol. 1995 Oct;13(10):2575-81.

PMID:
7595709
44.

Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome.

Tiersten AD, Grin CM, Kopf AW, Gottlieb GJ, Bart RS, Rigel DS, Friedman RJ, Levenstein MJ.

J Dermatol Surg Oncol. 1991 Jan;17(1):44-8.

PMID:
1991880

Supplemental Content

Loading ...
Support Center